Use of Nemolizumab in the Treatment of Prurigo Nodularis and Atopic Dermatitis., PMID:40403168
Nemolizumab Improves Pruritus in Patients With Intrinsic Atopic Dermatitis Lacking Atopic Predisposition: A Single-Centre Pilot Retrospective Cohort Study., PMID:40372094
Cutaneous Adverse Events Following Nemolizumab Administration: A Review., PMID:40364058
New and Emerging Biologics and Jak Inhibitors for the Treatment of Prurigo Nodularis: A Narrative Review., PMID:40282922
Topical Application of Fluoxetine Improves DNCB-Induced Atopic Dermatitis in Mice., PMID:40243303
Effectiveness and Safety of Nemolizumab in Patients with Prurigo Nodularis: a Systematic Review and Meta-Analysis of Randomized Controlled Trials., PMID:40205064
Phenotype-endotype relationship in elderly atopic dermatitis and effects of dupilumab therapy: prospective study., PMID:40095170
Elevated Type 2 Inflammatory Factors, Th2/Th1 Balanced Status, and Exosomes as a Marker of Severity in Chronic Actinic Dermatitis., PMID:39949921
WISIT vaccines based on IL-31-derived peptides as a novel therapeutic approach for chronic pruritic dermatoses., PMID:39932924
Pre- and Postnatal Development Study of Nemolizumab, a Humanized Anti-Interleukin-31 Receptor A Monoclonal Antibody, in Cynomolgus Monkey., PMID:39868832
Therapeutic potential of a systemically applied humanized monoclonal antibody targeting Toll‑like receptor 2 in atopic‑dermatitis‑like skin lesions in a mouse model., PMID:39781040
Type 2 cytokine-JAK1 signaling is involved in the development of dry skin-induced mechanical alloknesis., PMID:39616021
Predictive cytokines of omalizumab in the treatment of chronic spontaneous urticaria., PMID:39602877
Emerging Biologic Therapies for the Treatment of Atopic Dermatitis., PMID:39365406
Cytokine profile of the stratum corneum in atopic dermatitis lesions differs between the face and the trunk., PMID:39332980
Comparison of serum cytokines and chemokines levels and clinical significance in patients with pemphigus vulgaris-A retrospective study., PMID:39246287
Long-term use of lokivetmab in dogs with atopic dermatitis., PMID:39143659
Pharmacological Trends in the Management of Atopic Dermatitis: A Comprehensive Review., PMID:39130865
Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials., PMID:39067461
Clinical characteristics, immunological alteration and distinction of MOG-IgG-associated disorders and GFAP-IgG-associated disorders., PMID:39002186
Exploring the Potentiality of a Plant Platform for Monoclonal Antibody Production in Veterinary Medicine., PMID:38932349
IL-4 and IL-13 are not involved in IL-31-induced itch-associated scratching behaviour in mice., PMID:38855893
Inflammatory cytokine levels and changes during omalizumab treatment in chronic spontaneous urticaria., PMID:38795119
A comparative study of multiple biomarkers levels in complicated versus noncomplicated type 2 diabetic patients., PMID:38678628
Interleukin antagonists for atopic dermatitis: a new era of therapy., PMID:38656240
An OX-Tra'Ordinary Tale: The Role of OX40 and OX40L in Atopic Dermatitis., PMID:38607026
Altered COVID-19 immunity in children with asthma by atopic status., PMID:38590754
Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years., PMID:38563683
A case of bullous pemphigoid following administration of anti-IL-31 receptor A antibody., PMID:38507442
A Bispecific, Tetravalent Antibody Targeting Inflammatory and Pruritogenic Pathways in Atopic Dermatitis., PMID:38375189
GB12-09, a bispecific antibody targeting IL4Rα and IL31Rα for atopic dermatitis therapy., PMID:38371956
The IL-31/TRPV1 pathway mediates allergic asthma exacerbated by DINP dermal exposure in OVA-sensitized Balb/c mice., PMID:38154627
Blockade of OSMRβ signaling ameliorates skin lesions in a mouse model of human atopic dermatitis., PMID:38102969
Infiltration analysis of eosinophils and basophils and co-expression of CD69, CD63, IL-31 and IgE in patients with bullous and non-bullous pemphigoid., PMID:37907267
What Is New in Cutaneous T Cell Lymphoma?, PMID:37874473
Effects of Omalizumab on Serum Levels of Substance P, Calcitonin Gene-Related Peptide, Neuropeptide Y, and Interleukin-31 in Patients with Chronic Spontaneous Urticaria., PMID:37795408
Dupilumab for cancer-associated refractory pruritus., PMID:37779518
Serum cytokine profiles in myasthenia gravis with anti-muscle-specific kinase antibodies., PMID:37774555
IL-31-Pruritus Interleukin: Serum Values and Clinical Impact in Chronic Spontaneous Urticaria-A Romanian Retrospective Study., PMID:37762898
Clinical trials of antibody drugs in the treatments of atopic dermatitis., PMID:37727760
An atopic dermatitis-like murine model by skin-brushed cockroach Per a 2 and oral tolerance induction by Lactococcus lactis-derived Per a 2., PMID:37676892
English version of Japanese guidance for biologics in treating atopic dermatitis., PMID:37650357
Therapeutic potential of infliximab for pruritus in mice model of cholestasis induced by bile duct ligation: Possible involvement of IL-31., PMID:37597403
Canine interleukin-31 binds directly to OSMRβ with higher binding affinity than to IL-31RA., PMID:37588794
Correlation between clinical efficacy on pruritus and serum interleukin-31 levels in dogs with atopic dermatitis treated with lokivetmab., PMID:37389418
Biomarkers detected in cord blood predict vaccine responses in young infants., PMID:37251388
Equine allergic skin diseases: Clinical consensus guidelines of the World Association for Veterinary Dermatology., PMID:37154488
[Pharmacological profiles and clinical findings of nemolizumab as treatment for pruritus associated with atopic dermatitis]., PMID:37121713
Expression, purification, and biological characterization of recombinant human interleukin-31 protein., PMID:37096330
Emerging Systemic Treatments for Atopic Dermatitis., PMID:37072648
For research use only. Not for human or drug use.
